Total Payments
$303,745
2024 Payments
$9,563
Companies
4
Transactions
15
Payment Breakdown by Category
Research$301,726 (99.3%)
Consulting$2,000 (0.7%)
Food & Beverage$19.79 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $301,726 | 13 | 99.3% |
| Consulting Fee | $2,000 | 1 | 0.7% |
| Food and Beverage | $19.79 | 1 | 0.0% |
Payments by Type
Research
$301,726
13 transactions
General
$2,020
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $244,550 | 4 | $0 (2021) |
| Eli Lilly and Company | $57,176 | 9 | $0 (2024) |
| Celgene Corporation | $2,000 | 1 | $0 (2021) |
| Greenwich Biosciences, Inc. | $19.79 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,563 | 1 | Eli Lilly and Company ($9,563) |
| 2023 | $36,975 | 2 | Eli Lilly and Company ($36,975) |
| 2022 | $8,988 | 2 | Eli Lilly and Company ($8,988) |
| 2021 | $24,407 | 4 | E.R. Squibb & Sons, L.L.C. ($22,088) |
| 2020 | $37,025 | 4 | E.R. Squibb & Sons, L.L.C. ($35,675) |
| 2019 | $185,388 | 1 | E.R. Squibb & Sons, L.L.C. ($185,388) |
| 2018 | $1,400 | 1 | E.R. Squibb & Sons, L.L.C. ($1,400) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,562.50 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 06/07/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,287.50 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $28,687.50 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 12/07/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,300.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 09/08/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $688.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 10/28/2021 | Greenwich Biosciences, Inc. | Epidiolex (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Neurology | ||||||
| 04/14/2021 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 02/04/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 01/04/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $22,087.50 | Research |
| Study: Phase IIB 1L GBM Methylated nivo mono chemo RT • Category: Oncology | ||||||
| 11/06/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 03/11/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $175.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 02/03/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $175.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | ||||||
| 01/02/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $35,675.00 | Research |
| Study: Phase IIB 1L GBM Methylated nivo mono chemo RT • Category: Oncology | ||||||
| 01/02/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $185,387.50 | Research |
| Study: Phase IIB 1L GBM Methylated nivo mono chemo RT • Category: Oncology | ||||||
| 12/14/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: Phase IIB 1L GBM Methylated nivo mono chemo RT • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase IIB 1L GBM Methylated nivo mono chemo RT | E.R. Squibb & Sons, L.L.C. | $244,550 | 4 |
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $38,250 | 2 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $8,475 | 2 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $8,288 | 1 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $1,988 | 3 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $175.00 | 1 |
About Dr. John Tsiouris, MD
Dr. John Tsiouris, MD is a Psychiatry healthcare provider based in Staten Island, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356446553.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Tsiouris, MD has received a total of $303,745 in payments from pharmaceutical and medical device companies, with $9,563 received in 2024. These payments were reported across 15 transactions from 4 companies. The most common payment nature is "" ($301,726).
Ad
Practice Information
- Specialty Psychiatry
- Location Staten Island, NY
- Active Since 09/13/2006
- Last Updated 05/02/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1356446553
Products in Payments
- OPDIVO (Biological) $244,550
- Epidiolex (Drug) $19.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Staten Island
Dr. Waqar Siddiqui, Md, MD
Psychiatry — Payments: $62,243
Psychiatry $62,243
Dr. Mark Dibuono, Md, MD
Psychiatry — Payments: $43,469
Psychiatry $43,469
Vadim Azbel, Md, MD
Psychiatry — Payments: $27,482
Psychiatry $27,482
Aruna Agni, M.d, M.D
Psychiatry — Payments: $22,355
Psychiatry $22,355
Robert Stern, Md, MD
Psychiatry — Payments: $14,172
Psychiatry $14,172
Bolaji Bankole, M.d, M.D
Psychiatry — Payments: $8,873
Psychiatry $8,873